TY - JOUR
T1 - TAK1 targeting by glucocorticoids determines JNK and IκB regulation in toll-like receptor-stimulated macrophages
AU - Bhattacharyya, Sandip
AU - Ratajczak, Christine K.
AU - Vogt, Sherri K.
AU - Kelley, Crystal
AU - Colonna, Marco
AU - Schreiber, Robert D.
AU - Muglia, Louis J.
PY - 2010/3/11
Y1 - 2010/3/11
N2 - Glucocorticoids potently attenuate the production of inflammatory mediators by macrophages, a primary effector of innate immunity. Activation of different macrophage Toll-like receptors (TLRs) by their respective ligands presents a powerful system by which to evaluate stimulus-dependent glucocorticoid effects in the same cell type. Here, we test the hypothesis that glucocorticoids, acting through the glucocorticoid receptor, modulate macrophage activation preferentially depending upon the TLR-selective ligand and TLR adapters. We established that 2 adapters, Trif, MyD88, or both, determine the ability of glucocorticoids to suppress inhibitor of κB (IκB) degradation or Janus kinase (JNK) activation. Moreover, the sensitivity of transforming growth factor β-activated kinase 1 (TAK1) activation to glucocorticoids determines these effects. These findings identify TAK1 as a novel target for glucocorticoids that integrates their anti-inflammatory action in innate immunity signaling pathways.
AB - Glucocorticoids potently attenuate the production of inflammatory mediators by macrophages, a primary effector of innate immunity. Activation of different macrophage Toll-like receptors (TLRs) by their respective ligands presents a powerful system by which to evaluate stimulus-dependent glucocorticoid effects in the same cell type. Here, we test the hypothesis that glucocorticoids, acting through the glucocorticoid receptor, modulate macrophage activation preferentially depending upon the TLR-selective ligand and TLR adapters. We established that 2 adapters, Trif, MyD88, or both, determine the ability of glucocorticoids to suppress inhibitor of κB (IκB) degradation or Janus kinase (JNK) activation. Moreover, the sensitivity of transforming growth factor β-activated kinase 1 (TAK1) activation to glucocorticoids determines these effects. These findings identify TAK1 as a novel target for glucocorticoids that integrates their anti-inflammatory action in innate immunity signaling pathways.
UR - http://www.scopus.com/inward/record.url?scp=77950442119&partnerID=8YFLogxK
U2 - 10.1182/blood-2009-06-224782
DO - 10.1182/blood-2009-06-224782
M3 - Article
C2 - 20065289
AN - SCOPUS:77950442119
SN - 0006-4971
VL - 115
SP - 1921
EP - 1931
JO - Blood
JF - Blood
IS - 10
ER -